Cargando…

Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC

Biomarker testing is key for non-small cell lung cancer (NSCLC) management and plasma based next-generation sequencing (NGS) is increasingly characterized as a non-invasive alternative. This study aimed to evaluate the value of complementary circulating tumor DNA (ctDNA) NGS on tissue single-gene te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desmeules, Patrice, Dusselier, Matthieu, Bouffard, Cédrik, Bafaro, Josée, Fortin, Marc, Labbé, Catherine, Joubert, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858142/ https://www.ncbi.nlm.nih.gov/pubmed/36661694 http://dx.doi.org/10.3390/curroncol30010045

Ejemplares similares

Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers
por: Ruel, Louis-Jacques, et al.
Publicado: (2022)

Performance of an RNA-Based Next-Generation Sequencing Assay for Combined Detection of Clinically Actionable Fusions and Hotspot Mutations in NSCLC
por: Desmeules, Patrice, et al.
Publicado: (2022)

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC
por: Křížová, Ľudmila, et al.
Publicado: (2022)

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023)

P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO TISSUE BIOPSIES FOR THE MOLECULAR CLASSIFICATION OF DLBCL PATIENTS
por: Moia, R., et al.
Publicado: (2022)

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
por: Papadopoulou, Eirini, et al.
Publicado: (2019)

Liquid biopsy in NSCLC: a new challenge in radiation therapy
por: Perillo, Annarita, et al.
Publicado: (2021)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
por: Pasini, Luigi, et al.
Publicado: (2019)

Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC
por: Mellert, Hestia, et al.
Publicado: (2021)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
por: Słomka, Artur, et al.
Publicado: (2022)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC
por: Li, Yilin, et al.
Publicado: (2023)

Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
por: Jackson, Leisa P., et al.
Publicado: (2020)

The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Sama, Srikar, et al.
Publicado: (2022)

Liquid biopsy genotyping in lung cancer: ready for clinical utility?
por: Huang, Wei-Lun, et al.
Publicado: (2017)

Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach
por: Hofman, Paul
Publicado: (2023)

Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC)
por: Sardarabadi, Parvaneh, et al.
Publicado: (2021)

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients
por: Sanchez-Cabrero, Darío, et al.
Publicado: (2023)

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021)

Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
por: Thompson, Jeffrey C., et al.
Publicado: (2022)

Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients
por: Vollbrecht, Claudia, et al.
Publicado: (2018)

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
por: Sesé, Marta, et al.
Publicado: (2019)

Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC
por: Kim, In Ae, et al.
Publicado: (2022)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
por: Nigro, Maria Concetta, et al.
Publicado: (2023)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
por: Barr, Martin P., et al.
Publicado: (2022)

Tumor‐proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells
por: Buscail, Etienne, et al.
Publicado: (2019)

A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced NSCLC patients
por: Kim, In Ae, et al.
Publicado: (2023)

Liquid biopsy reveals collateral tissue damage in cancer
por: Lubotzky, Asael, et al.
Publicado: (2022)

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC
por: Schwartzberg, Lee S., et al.
Publicado: (2022)

Liquid biopsy: from discovery to clinical implementation
por: Alix‐Panabières, Catherine, et al.
Publicado: (2021)

A Simplified Version of the IASLC Grading System for Invasive Pulmonary Adenocarcinomas With Improved Prognosis Discrimination
por: Bossé, Yohan, et al.
Publicado: (2023)

Liquid biopsy in lymphoma
por: Rossi, Davide, et al.
Publicado: (2019)

Liquid Biopsy in Glioblastoma
por: Ronvaux, Lorian, et al.
Publicado: (2022)

Liquid biopsy and glioblastoma
por: Eibl, Robert H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m0dp7t19fsbrhd2fpsro1be3pu